Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Ipca Laboratories is currently trading at Rs 467.80, up by 5.00 points or 1.08% from its previous closing of Rs 462.80 on the BSE.
The scrip opened at Rs 465.00 and has touched a high and low of Rs 477.00 and Rs 464.00 respectively. So far 46814 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 495.00 on 01-Oct-2012 and a 52 week low of Rs 234.05 on 23-Nov-2011.
Last one week high and low of the scrip stood at Rs 466.95 and Rs 449.50 respectively. The current market cap of the company is Rs 5881.13 crore.
The promoters holding in the company stood at 45.91% while Institutions and Non-Institutions held 33.80% and 20.29% respectively.
Ipca Laboratories has reported a surge of 60.45% in its net profit at Rs 125.09 crore for the quarter ended September 30, 2012 as compared to Rs 77.96 crore for the same quarter in the previous year. The company’s total income has increased by 24.56% at Rs 780.45 crore for quarter under review as compared to Rs 626.55 crore for the quarter ended September 30, 2011.
Pursuant to the scheme of amalgamation of Tonira Pharma with the Company with effect from appointed date April 01, 2011, the results of operations for the quarter and half year ended September, 2012 includes the operations of the business of erstwhile Tonira. Since this effect of amalgamation was given in the quarter ended March, 2012, the figure of the comparative quarter and half year ended September, 2011 does not include the result of operations of the erstwhile Tonira and hence not comparable.
Further, the company’s board of directors at its meeting held on October 25, 2012, has declared an interim dividend of 100% (Rs 2 per share) for the financial year 2012-13.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1462.50 |
| Dr. Reddys Lab | 5784.50 |
| Cipla | 1451.25 |
| Zydus Lifesciences | 1001.15 |
| Lupin | 1587.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
